Loading...
•
Jan 31, 2024
KalVista Q3 2024 Earnings Report
KalVista reported positive phase 3 KONFIDENT data and completed a substantial financing.
Key Takeaways
KalVista Pharmaceuticals reported its third fiscal quarter results with key highlights including positive topline data from the Phase 3 KONFIDENT clinical trial and the completion of an underwritten offering that yielded approximately $150.1 million in net proceeds.
Phase 3 KONFIDENT clinical trial met all primary and key secondary endpoints and demonstrated a favorable safety profile.
Closed an underwritten offering with net proceeds of approximately $150.1 million, expected to provide funding into 2026.
Benjamin L. Palleiko was appointed as Chief Executive Officer.
The UK MHRA awarded the Innovation Passport for sebetralstat.
Forward Guidance
KalVista anticipates submitting a new drug application to the U.S. Food and Drug Administration (FDA) for sebetralstat in the first half of 2024 and expects to file for approval in Europe and Japan later in 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...